Abstract: The invention provides atropine sulfate (AS) rapidly-disintegrating sublingual tablets (RDSTs) of improved formulation in a sublingual dosage form and methods for therapeutic use of the AS RDSTs for treatment of organophosphate (OP) exposure and acute toxicity. The AS RDSTs provide an alternative easy-to-use dosage form for the management of organophosphate toxicity. Additionally, the invention provides methods for improved formulation and quality evaluation of the atropine sulfate rapidly-disintegrating sublingual tablets.

Abstract: A botanical matrix and a base are disclosed for use in producing vapes. The base includes propanediol, vegetal glycerin and a blend of two or more botanical additives. The propanediol and glycerin may be lab produced for improved consistency. Additional ingredients including active ingredients may be added to the base to produce a vape. The botanical additives provide a base that has a smoother impression and reduces or eliminates throat burn.

Abstract: A single use applicator described herein allows for simplicity while ensuring that only the necessary amount of product in each compartment is utilized when needed. The inventive drug delivery device comprises a housing with two compartments, each containing substances separated by a barrier or membrane which can be broken apart by applying pressure to the housing. One end of the applicator comprises a tapered nozzle and cap which can be twisted off when ready to use. Once the barrier or membrane is broken, the two components, liquid and powder, will mix creating the end product. After the two components have been mixed and the user is ready to apply the end product, the user will twist the cap off of the device and apply pressure to the applicator housing in order to force the substance through the nozzle and into the eye, nasal passage, ear canal or other part of the body.

Abstract: Topical compositions comprising sunflower oil, coconut oil, shea butter, grapeseed oil, squalene, and a tocopherol are disclosed. Topical compositions comprising sunflower oil, coconut oil, shea butter, camellia oil, squalane, and a tocopherol are further disclosed. Topical compositions comprising sunflower oil, coconut oil, shea butter, camellia oil, squalane, menthol and a tocopherol are disclosed. Topical compositions comprising sunflower oil, coconut oil, shea butter, camellia oil, squalane, hemp oil and a tocopherol are also disclosed. Topical compositions comprising sunflower oil, coconut oil, shea butter, camellia oil, squalane, menthol, hemp oil and a tocopherol are also disclosed. The compositions disclosed herein can be used for improving various skin conditions, such as eczema, erythema, irritation, pruritus, drying, drying of the skin, cracking of the skin, wrinkles, rosacea, contact dermatitis, and atopic dermatitis.

Abstract: A method of treating a fungal infection may include formulating a topical treatment solution comprising combining itraconazole oral solution, 10 mg/mL, and a diluent. The itraconazole oral solution, 10 mg/mL, may include propylene glycol and at least one of cherry flavor or caramel flavor. The method may also include topically administering the topical treatment solution to the subject by contacting an infected skin surface of the subject with the topical treatment solution.

Abstract: Compositions, e.g., gels, useful for tissue resection procedures, medical devices comprising the compositions, and related methods of preparing the compositions are discussed. The composition may comprise gellan gum, two or more salts, and water. In some aspects, the composition may be prepared by combining gellan gum and water to form a pre-mixture, heating the pre-mixture, adding two or more salts to the heated pre-mixture to form a mixture, introducing the mixture into a reservoir, and allowing the mixture to form a gel inside the reservoir. The gel may have a continuous, three-dimensional structure, and have desired gel strength and viscosity. The composition may be biocompatible and injectable from the reservoir through a needle to the target site of a patient.

Abstract: The disclosure provides an ophthalmic formulation comprising a bromodomain inhibitor, a polar aprotic solvent (e.g., dimethyl sulfoxide (DMSO)), polysorbate, salt, and Captisol, as well as a method of treating or preventing ophthalmic inflammation in a subject in need thereof comprising locally administering the formulation to the eye of the subject.

Abstract: An inhalable powder composition comprises a) an antagonistic antibody which binds human IL-13, b) leucine and c) trehalose. The antibody may comprise a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:3 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:1. Also described is the use of such compositions in the treatment of asthma, as well as inhalers containing such compositions.

Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

Abstract: A drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate or polymorph thereof, where the telmisartan has a concentration of 1 to 10 mg/ml within the drinkable pharmaceutical solution, and the drinkable pharmaceutical solution has a pH of 10.

Abstract: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.

Abstract: Stable formulation of L-cysteine hydrochloride amenable to terminal sterilization; a terminally sterilized stable formulation of L-cysteine hydrochloride; a process of manufacturing a stable formulation of L-cysteine hydrochloride amenable to terminal sterilization; and a container comprising the formulations of the invention.

Abstract: According to the present invention, there is provided a liquid formulation for oral administration comprising an active pharmaceutical ingredient dispersed in a pharmaceutically acceptable oily carrier, the oily carrier comprising a major proportion of a triglyceride-based oil and a minor proportion of a waxy compound.

Abstract: The invention concerns a lipid composition that is self-emulsifying in the presence of a hydrophilic phase, comprising between 0.001% and 20% by weight, relative to the total weight of the composition, of at least one active substance; between 5% and 60% by weight, relative to the total weight of the composition, of an oily phase; a first surfactant; a second surfactant; the ratio between the first surfactant and the second surfactant being between 0.5 and 6; said lipid composition is such that, after dispersion in the hydrophilic phase, it forms particles having, as an absolute value, a charge of between 10 mV and 100 mV. The invention also concerns a method for preparing a self-emulsifying lipid composition, and the use of said self-emulsifying lipid composition in the pharmacutical or nutraceutical veterinary field.

Abstract: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Abstract: The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Abstract: Provided herein is a composite microparticle for oral delivery of an active agent to a subject. The microparticles are general in the form of self-sustaining bodies comprising a crosslinked polymer matrix and a plurality of emulsion droplets distributed throughout. The active agent is encapsulated in the emulsion droplets. A plurality of delivery enhancing moieties are presented on the exterior surface of said self-sustaining body and/or on the emulsion droplets. The microparticle is resistant to enteric degradation and will localize in the gastrointestinal tract of the subject without crossing the intestinal mucosa into the intestinal bloodstream.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.

Abstract: A particle-producing method is provided including the processes of: discharging a liquid from discharge holes provided on a liquid-storing unit storing the liquid to make the liquid into droplets, the liquid containing a physiologically active substance and a polymer; and solidifying the droplets into a particle.

Abstract: The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I).

Abstract: Provided are a composite capsule and a method of preparing the composite capsule. The composite capsule includes a first dissolving part including a core, an inner coating layer on the core, and a first enteric coating layer on the inner coating layer, wherein core contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof. The composite capsule further includes a second dissolving part including a core, which contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof, an inner coating layer on the core, and a second enteric coating layer on the inner coating layer.

Abstract: Provided herein are therapeutic agents comprising an elastin-like peptide (ELP) component and a ligand that specifically targets and binds an ICAM-1 receptor. In one aspect, the ELP comprises, or alternatively consists essentially of, or yet further consists of one or more sequence(s) designated S48I48 and/or mICMA-1 SI and/or hICAM-1 S1 or biological equivalents thereof. In a further aspect, the ELP/ligand composition further comprises a therapeutic agent. In one aspect, the therapeutic agent is specific to the treatment or amelioration of symptoms associated with autoimmune disorders such as SjS.

Abstract: Proteinoid compounds characterized by a molecular weight (Mw) of at least 15,000 Da, processes of preparing such compounds and methods of use thereof, are provided. A method of monitoring the presence and metastases of cancer in a body of an individual is further disclosed.

Abstract: This invention relates to medical science and pharmaceutical technology. A new type of finished pharmaceutical form with individual medicine dosing capability is described comprising a storage container and a carrier on which the medicine is applied. Methods of production and use of the finished pharmaceutical form for individual medicine dosing are suggested.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Suggested is an active mixture comprising (a) 1,2-hexanediol and (b) 1,2-octanediol.

Abstract: The present application relates to a plant-soaked solution including a saccharide containing allulose and a method of preparing the same.

Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Abstract: Oxidative stress is linked to several health conditions including, without limitation, cancer, aging, neurodegenerative and metabolic diseases. Increased levels of oxidative stress may result from increased exposure to radiation or other environmental stressors and/or diminished protective effects of cellular defenses against reactive oxygen species. The present disclosure provides compositions and methods comprising encapsulated cannabinoid compounds useful for reducing oxidative stress in a subject.

Abstract: The present invention provides methods related to Wolf-Hirschhom syndrome (WHS), in particular to a 197 kbp chromosomal deletion useful for selecting a patient for anti-seizure therapy (e.g., cannabidiol, vitamin B6, and butyrate), for selecting a particular anti-seizure therapy, and for predicting the response of a subject to a particular anti-seizure therapy.

Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Abstract: A pharmaceutical dosage form is disclosed having a breaking strength of at least 300 N and comprising (i) an ephedrine component selected from the group consisting of ephedrine, pseudoephedrine and the physiologically acceptable salts thereof, wherein preferably the weight content of the ephedrine component is within the range of from 0.1 to 60 wt.-%, relative to the total weight of the pharmaceutical dosage form; and (ii) a physiologically acceptable conversion inhibitor that is capable of inhibiting the chemical conversion ex vivo of the ephedrine component into methamphetamine. Also disclosed is a method of treating a disease, disorder or condition, preferably selected from the group consisting of tissue hyperemia, edema, and nasal congestion, comprising the administration of the pharmaceutical dosage form to a subject in need thereof.

Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.

Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.

Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Abstract: The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. The method is also applicable to apoptosis associated with administration of topic stuimuli for treatment of cancer, that produced by viral infections, autoimmune diseases or Aquired Immuno Defficiency Syndrome. The ketosis produced is a state in which levels of one or both of acetoacetate and (R)-3-hydroxybutyrate concentrations in the mood of the subject such that their total concentration in the blood is elevated above the normal fed levels to between 0.1 and 30 mM.

Abstract: The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).

Abstract: Disclosed herein are methods and compositions for treating, inhibiting, or reducing hair loss, treating, inhibiting, or reducing pigmentation loss, improving or stimulating hair growth, and/or improving or stimulating pigmentation production in a subject with one or more alpha-ketobutyrate compounds and/or one or more glutarate compounds.

Abstract: A composition comprising as a sole active ingredient fenofibric acid or one of the pharmaceutically acceptable salts thereof for use in the treatment of liver diseases. The field relates to the treatment and prevention of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis or cirrhosis.

Abstract: An anti-inflammatory composition is disclosed. The anti-inflammatory composition is useful for a pharmaceutical composition or a cosmetic composition by not only having excellent stability on the skin and therefore being harmless to the human body, but also by controlling the expression of an inflammatory skin disease-related mediating factor and thereby exhibiting an excellent anti-inflammatory effect.

Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.